Press releases

9 December, 2024

Abliva Announces Publication of Results from Phase 1a/b Study of KL1333 in the Scientific Journal Brain

-Results demonstrated that KL1333 was safe and well tolerated, with early signs of efficacy in patients with primary mitochondrial disease- Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company ...

16 September, 20249 December, 2024

Join Abliva for World Mitochondrial Disease Week 2024, September 16 – 22

-The company shares videos each day of the week to raise awareness about mitochondrial disease and to highlight ongoing activities at Abliva- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage compa ...

18 July, 2024

Regulatory

Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease

-Independent committee confirms FALCON study is powered for potential success with both alternative endpoints passing futility- -Committee confirms strong safety profile of KL1333- -Abliva to hos ...

30 May, 2024

Abliva Announces Completion of 24 Weeks of Dosing in Wave 1 of the FALCON Study of KL1333 in Primary Mitochondrial Disease

-With 24 weeks of dosing complete, Abliva remains on track to report the interim analysis in early Q3 2024- Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for [&helli ...

23 May, 2024

Regulatory

Resolutions from Annual General Meeting in Abliva AB (publ) on May 23, 2024

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 23, 2024, held its Annual General Meeting (“AGM”). A summary of the resolution follows.

13 May, 2024

Abliva to Host Virtual KOL Event on KL1333 in Primary Mitochondrial Disease on May 21, 2024

Lund, Sweden, May 13, 2024 — Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it w ...

22 April, 2024

Regulatory

Notice of Annual General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, (“the Company or “Abliva”) are hereby convened to the Annual General Meeting, held at 1 p.m. on Thursday, 23 May 2024 at Me ...

26 March, 2024

Regulatory

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today 26 March 2024 held an Extraordinary General Meeting. A summary of the resolutions follows. The resolutions were passed unanimou ...

22 February, 2024

Regulatory

Notice of Extraordinary General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, (the “Company”), are hereby convened to the Extraordinary General Meeting (the “EGM”) to be held at 3 p.m. on Tuesday 26 Ma ...

20 December, 202319 February, 2024

Abliva Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that the goal of enrolling 40 patients ...

14 December, 202319 February, 2024

Abliva Receives Orphan Designation from the European Commission for its Drug Candidate NV354

Abliva AB (Nasdaq Stockholm: ABLI) a clinical-stage company developing medicines for the treatment of rare and severe primary mitochondrial disease, today announced that the European Commission has gr ...

14 November, 202319 February, 2024

Regulatory

Abliva and Owl Therapeutics enter into licensing and collaboration agreement for NeuroSTAT® in Traumatic Brain Injury

Abliva AB (‘Abliva’ or the ‘Company’) and US-based Owl Therapeutics today announced the signing of a licensing and collaboration agreement for Abliva’s NeuroSTAT® for the treatment of moderate to seve ...